Personalized Kampo Medicine Facilitated Both Cytotoxic T Lymphocyte Response and Clinical Benefits Induced by Personalized Peptide Vaccination for Advanced Esophageal Cancer

Table 1

Patients’ characteristics ().

Parameters	PPV with PKM ()	PPV without PKM ()	value
Age: median (range)	64 (39–82)	60 (43–72)	0.08
Gender: male (female)	18 ()	9 ()	0.81
Performance status
0	18	7	0.37
1	4	3	0.51
2	1	1	0.58
Histology
Adenocarcinoma	1	1	0.58
Carcinosarcoma	0	1	0.14
Squamous cell carcinoma	21	8	0.15
Small cell carcinoma	0	1	0.14
Neuroendocrine cell carcinoma	1	0	0.48
Clinical stage
III	3	2	0.69
IV	17	7	0.54
Recurrence	3	2	0.69
Prior surgery	9	5	0.73
Prior radical radiation	15	5	0.27
Previous chemotherapy (regimens)
0	2	1	0.97
1	5	2	0.81
2	8	6	0.27
≧3	8	2	0.32
Median vaccinations (range)	10 (1–19)	6 (2–21)	0.90
Combination chemotherapy
None	12	6	0.90
FP (5-FU + CDDP)	1	1	0.58
AMR	1	0	0.48
DCF (DTX + CDDP + 5-FU)	1	0	0.48
TS-1	2	0	0.31
UFT	0	1	0.14
CPA	3	0	0.21
DTX	3	2	0.69
DTX-NPs	0	1	0.14

5-FU: 5-fluorouracil, CDDP: cisplatin, AMR: amrubicin, DTX: docetaxel, TS-1: tegafur/gimeracil/oteracil combination, UFT: tegahur-uracil, CPA: cyclophosphamide, and NPs: nanoparticles.